United States

Saumya Joseph

U.S. health spending to rise 5.5 percent per year over next decade: CMS

Feb 20 2019

U.S. health spending is expected to grow at an average rate of 5.5 percent every year from 2018 over the next decade and will reach nearly $6 trillion by 2027 as more people become eligible for Medicare, a government health agency said on Wednesday.

Medtronic quarterly profit beats on strength in surgical products

Feb 19 2019

Medtronic Plc beat analysts' estimates for quarterly profit on Tuesday, boosted by sales of its surgical products, and the largest U.S. standalone medical device maker raised the upper end of its full-year earnings forecast.

Johnson & Johnson's nasal spray for depression wins FDA panel backing

Feb 12 2019

An advisory panel to the U.S. Food and Drug Administration on Tuesday voted in favor of Johnson & Johnson's experimental nasal spray, which has a compound similar to often-abused ketamine, bringing the drug closer to approval.

Cigna CEO shrugs off concerns about proposed change to rebate rules

Feb 01 2019

The U.S. government's proposal to eliminate rebates that pharmacy benefit managers receive from drugmakers will not have a meaningful impact on growth, and does not affect the commercial market, Cigna Corp Chief Executive Officer David Cordani said on Friday.

Anthem speeds up pharmacy benefits launch, shares jump 10 percent

Jan 30 2019

Anthem Inc surprised Wall Street on Wednesday by moving up the launch of its in-house pharmacy benefits management business, sending shares 10 percent higher as investors welcomed the decision after rival health insurers signed multibillion-dollar deals joining forces with PBMs.

FDA advisory panel split over Sanofi-Lexicon diabetes drug

Jan 17 2019

An advisory panel to the U.S. Food and Drug Administration was divided over whether to recommend approval of a treatment for type 1 diabetes developed by Lexicon Pharmaceuticals Inc and France's Sanofi SA.

Amgen's postmenopausal osteoporosis drug wins FDA panel backing

Jan 16 2019

An advisory panel to the U.S. Food and Drug Administration said on Wednesday that benefits of Amgen Inc's osteoporosis treatment for postmenopausal women at high risk for fracture outweighed its risks and overwhelmingly voted for the drug's approval.

Walmart opts to leave CVS partnerships over pricing dispute

Jan 15 2019

CVS Health Corp said on Tuesday Walmart Inc is leaving its network for commercial and Medicaid prescription drug plans after the two companies failed to agree on pricing.

World News